share_log

T2 Biosystems | 8-K: T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems | 8-K: T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems | 8-K：T2 Biosystems 公佈2024年第三季度財務業績
美股SEC公告 ·  2024/11/15 22:59

Moomoo AI 已提取核心訊息

T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, announced its financial results for the third quarter ended September 30, 2024. The company reported a 34% increase in total revenue, reaching $2.0 million, compared to the same period in the previous year. This growth was primarily driven by a 34% rise in sepsis test panel revenue, largely due to increased U.S. sales of the T2Bacteria Panel. T2 Biosystems also executed contracts for 11 T2Dx Instruments, expanded its U.S. market access through an exclusive distribution agreement with Cardinal Health, and launched a co-marketing collaboration with Prxcision, Inc. Additionally, the company received FDA clearance to market the T2Candida Panel for pediatric patients and is advancing the T2Resistance Panel towards FDA 510(k) submission, expected in the first quarter of 2025. Despite these advancements, the company reported a net loss of $10.1 million, or $(0.57) per share, for the quarter. As of September 30, 2024, T2 Biosystems had cash and cash equivalents of $2.1 million and raised $4.3 million in net proceeds through an ATM during the quarter.
T2 Biosystems, a leader in rapid detection of sepsis-causing pathogens, announced its financial results for the third quarter ended September 30, 2024. The company reported a 34% increase in total revenue, reaching $2.0 million, compared to the same period in the previous year. This growth was primarily driven by a 34% rise in sepsis test panel revenue, largely due to increased U.S. sales of the T2Bacteria Panel. T2 Biosystems also executed contracts for 11 T2Dx Instruments, expanded its U.S. market access through an exclusive distribution agreement with Cardinal Health, and launched a co-marketing collaboration with Prxcision, Inc. Additionally, the company received FDA clearance to market the T2Candida Panel for pediatric patients and is advancing the T2Resistance Panel towards FDA 510(k) submission, expected in the first quarter of 2025. Despite these advancements, the company reported a net loss of $10.1 million, or $(0.57) per share, for the quarter. As of September 30, 2024, T2 Biosystems had cash and cash equivalents of $2.1 million and raised $4.3 million in net proceeds through an ATM during the quarter.
t2 biosystems作爲快速檢測導致膿毒症病原體的領導者，公佈了截至2024年9月30日的第三季度財務業績。公司報告總營業收入增長34%，達到200萬美元，與去年同期相比。此增長主要得益於膿毒症檢測面板收入增長34%，這主要是由於T2Bacteria面板在美國銷售增加。t2 biosystems還簽署了11台T2Dx儀器的合同，通過與卡地納健康的獨家分銷協議擴大了其在美國的市場準入，並與Prxcision, Inc.啓動了聯合市場推廣合作。此外，公司獲得了FDA的批准，可以向兒科患者推廣T2Candida面板，並正在推進T2Resistance面板的FDA 510(k)提交，預計將在2025年第一季度進行。儘管取得了這些進展，公司在本季度報告淨虧損1010萬美元，即每股（0.57）美元。截至2024年9月30日，t2 biosystems的現金及現金等價物爲210萬美元，並在本季度通過ATM籌集了430萬美元的淨收益。
t2 biosystems作爲快速檢測導致膿毒症病原體的領導者，公佈了截至2024年9月30日的第三季度財務業績。公司報告總營業收入增長34%，達到200萬美元，與去年同期相比。此增長主要得益於膿毒症檢測面板收入增長34%，這主要是由於T2Bacteria面板在美國銷售增加。t2 biosystems還簽署了11台T2Dx儀器的合同，通過與卡地納健康的獨家分銷協議擴大了其在美國的市場準入，並與Prxcision, Inc.啓動了聯合市場推廣合作。此外，公司獲得了FDA的批准，可以向兒科患者推廣T2Candida面板，並正在推進T2Resistance面板的FDA 510(k)提交，預計將在2025年第一季度進行。儘管取得了這些進展，公司在本季度報告淨虧損1010萬美元，即每股（0.57）美元。截至2024年9月30日，t2 biosystems的現金及現金等價物爲210萬美元，並在本季度通過ATM籌集了430萬美元的淨收益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Check-Cap
    CHEK
    -- 1.7700
    Inotiv
    NOTV
    -- 5.030
    Exagen
    XGN
    -- 3.580
    Grail
    GRAL
    -- 19.450
    VolitionRX
    VNRX
    -- 0.673

    解鎖榜首股票